Impel Pharmaceuticals Inc. (NASDAQ:IMPL – Get Rating) – Wedbush issued their FY2027 earnings estimates for shares of Impel Pharmaceuticals in a research note issued on Monday, January 23rd. Wedbush analyst L. Chico expects that the company will post earnings of $1.16 per share for the year. Wedbush currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Impel Pharmaceuticals’ current full-year earnings is ($4.63) per share.
IMPL has been the topic of several other research reports. Cowen lowered their price target on shares of Impel Pharmaceuticals to $40.00 in a research report on Thursday, November 17th. Guggenheim decreased their target price on shares of Impel Pharmaceuticals to $14.00 in a research report on Monday, November 21st.
Impel Pharmaceuticals Price Performance
Impel Pharmaceuticals (NASDAQ:IMPL – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.44). The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $5.16 million. Impel Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 701.26%.
Institutional Trading of Impel Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in IMPL. Vanguard Group Inc. increased its position in Impel Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 531,784 shares of the company’s stock valued at $3,387,000 after acquiring an additional 40,032 shares during the period. DCF Advisers LLC increased its position in Impel Pharmaceuticals by 19.5% in the 2nd quarter. DCF Advisers LLC now owns 438,566 shares of the company’s stock valued at $4,087,000 after acquiring an additional 71,508 shares during the period. State Street Corp increased its position in Impel Pharmaceuticals by 6.6% in the 1st quarter. State Street Corp now owns 180,045 shares of the company’s stock valued at $1,147,000 after acquiring an additional 11,107 shares during the period. Opaleye Management Inc. acquired a new position in Impel Pharmaceuticals in the 2nd quarter valued at about $1,348,000. Finally, Millennium Management LLC purchased a new stake in Impel Pharmaceuticals in the 2nd quarter valued at approximately $1,344,000. Institutional investors and hedge funds own 63.92% of the company’s stock.
About Impel Pharmaceuticals
Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- Get a free copy of the StockNews.com research report on Impel Pharmaceuticals (IMPL)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.